Accessibility Menu
LadRx logo

LadRx(OTC) LADX

Market Cap$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1988)-100%
5 Year-100%
1 Year-98%
1 Month+0%
$0.01
+0.00%
+0.00Today
LadRx last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-13
LadRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-08-06
1 month+0%USD 0.012026-07-10
3 month-89.72%USD 0.112026-05-14
Year to date+0%USD 0.012025-12-31
1 year-98.31%USD 0.652025-08-13
3 year-99.45%USD 2.002023-08-14
5 year-99.98%USD 72.982021-08-13
Since inception-100%USD 52,506.581988-04-05

LadRx Financials at a Glance

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.92K

Net Income (TTM)

-$2.50M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-11.86 (Low)

Price

$0.01

Volume

1

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $2.15

Estimated Earnings Date

May 12, 2026

LADX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About LadRx

LadRx Corporation is a biopharmaceutical company focused on the research and development of innovative chemotherapeutic drugs for solid tumors. The company utilizes its proprietary linker activated drug release (LADR) technology to deliver targeted treatments, aiming to improve patient outcomes in oncology.

Products and Services
  • Linker activated drug release (LADR) technology for targeted chemotherapy
  • Lead candidates include LADRs 7, 8, 9, and 10 for tumor treatment
  • Development of albumin companion diagnostic (ACDx) for patient identification
Growth Outlook
  • Ongoing phase II clinical development of aldoxorubicin for pancreatic cancer
  • Potential market expansion with novel drug candidates targeting solid tumors
  • Strategic focus on enhancing R&D capabilities to drive innovation
Financial Highlights
  • Recent quarterly revenue of 0, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) net income shows significant losses, indicating heavy investment in development
  • Cash and cash equivalents of $206,948 as of March 31, 2025, supporting operational needs
LadRx Corporation is positioned in the biotechnology sector, with a focus on developing advanced therapies for cancer treatment. The company's innovative LADR technology aims to enhance the efficacy of chemotherapy by delivering drugs directly to tumor sites, potentially reducing side effects and improving patient outcomes. The growth outlook remains promising, particularly with the ongoing clinical trials and the development of new drug candidates. Despite recent financial challenges, including a lack of revenue and significant net losses, the company is committed to advancing its research initiatives. The cash reserves provide a foundation for continued operations and development efforts. Investors may find interest in the company's unique approach to cancer treatment and its potential to capture market share in the biopharmaceutical industry. The strategic focus on R&D and the advancement of its product pipeline could lead to significant breakthroughs in oncology, making LadRx Corporation a noteworthy entity in the healthcare sector.
AI Generated • Aug 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

Stephen Snowdy, PhD, MBA

Website

www.ladrxcorp.com

Headquarters

Los Angeles, CA 90049, US

LADX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

242316.18%

Return on Capital

N/A

Return on Assets

-189358.22%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

495.10K

Volume

1

Avg. Volume

16.156

Financials (TTM)

Gross Profit

$257.00

Operating Income

-$3.51M

EBITDA

-$3.51M

Operating Cash Flow

-$1.86B

Capital Expenditure

$0.00

Free Cash Flow

-$1.86B

Cash & ST Invst.

$206.95K

Total Debt

$0.00

LadRx Performance Analysis

LadRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
LadRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
LadRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -3,551.50N/A
20222022-12-31USD -1,098.30-69.1%
20232023-12-31USD 0.68N/A
20242024-12-31USD -3.21N/A
LadRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-781.6%
Q32024-09-3035.5%
Q42024-12-31140.1%
Q12025-03-31-316.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$639.00

+69.0%

Gross Margin

0.00%

N/A

Market Cap

$5.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.70K

N/A

Employees

2

N/A

Net Income

-$719.29K

-485.2%

EBITDA

-$718.81K

+13.4%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$206.95K

-90.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1893.58%

N/A

Return on Invested Capital

2.55%

N/A

Free Cash Flow

-$552.79M

-9394767.4%

Operating Cash Flow

-$552.79M

-9394767.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DNAGDNAPrint Genomics, Inc.
$0.00+0.00%
NNBPNanobac Pharmaceuticals, Incorporated
$0.00+0.00%
MRPIMera Pharmaceuticals, Inc.
$0.00+0.00%
MHTXManhattan Scientifics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$115.67+0.04%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$48.42-0.05%
IBITiShares Bitcoin Trust
$44.72+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.27+0.02%

Questions About LADX

What is the current price of LadRx?

LadRx is trading at $0.01 per share.

What is the 52-week range for LadRx?

Over the past 52 weeks, LadRx has traded between $0.00 and $2.15.

How much debt does LadRx have?

As of the most recent reporting period, LadRx reported total debt of $0.00.

How much cash does LadRx have on hand?

LadRx reported $206.95K in cash and cash equivalents in its most recent financial results.

What is LadRx’s dividend yield?

LadRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services